Nada Babovic
2 Papers
Nada Babovic is an academic researcher. The author has contributed to research in topics: Placebo & Population. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio,Karl D. Lewis,Lev V. Demidov,Mario Mandalà,Igor Bondarenko,Paolo A. Ascierto,Christopher Herbert,Andrzej Mackiewicz,Piotr Rutkowski,Alexander Guminski,Grant R. Goodman,B. Simmons,Chenglin Ye,Yibing Yan,Dirk Schadendorf,Gabriela Cinat,Luis Fein,Michael C. Brown,Andrew Haydon,Adnan Khattak,Catriona M. McNeil,Phillip Parente,Jeremy Power,Rachel Roberts-Thomson,Shahneen Sandhu,Craig Underhill,Suresh Varma,Thomas Berger,Ahmad Awada,Nathalie Blockx,Veronique Buyse,Jeroen Mebis,Fabio Franke,Sergio J Azevedo,Nicolas Silva Lazaretti,Rahima Jamal,Catalin Mihalcioiu,Teresa M. Petrella,Kerry J. Savage,Xinni Song,Ralph Wong,Nina Dabelic,Stjepko Plestina,Zeljko Vojnovic,Petr Arenberger,Ivo Kocak,Ivana Krajsová,Eugen Kubala,Bohuslav Melichar,Yvetta Vantuchova,Kadri Putnik,Brigitte Dréno,Caroline Dutriaux,Jean-Jacques Grob,Pascal Joly,Jean-Philippe Lacour,Nicolas Meyer,Laurent Mortier,Luc Thomas,Michael Fluck,Thilo Gambichler,Jessica C. Hassel,Axel Hauschild,Paul Donnellan,John McCaffrey,Derek G. Power,Samuel Ariad,Gil Bar-Sela,Daniel Hendler,Ilan G. Ron,Jacob Schachter,Paolo A. Ascierto,Alfredo Berruti,Luca Bianchi,Vanna Chiarion Sileni,Francesco Cognetti,Riccardo Danielli,Anna Maria Di Giacomo,Luca Gianni,Aron Goldhirsch,Michele Guida,Paolo Marchetti,Paola Queirolo,Armando Santoro,Ellen Kapiteijn,Paula Ferreira,Georgy Gafton,Yulia Makarova,Zoran Andric,Nada Babovic,Darjana Jovanovic,Lidija Sekulovic,Graham Lawrence Cohen,Lydia Dreosti,Daniel A. Vorobiof,Maria Teresa Curiel Garcia,Roberto Diaz Beveridge,Margarita Majem Tarruella,Ivan Marquez Rodas,Jose-M Puliats Rodriguez,Antonio Rueda Dominguez,Marianne Maroti,Karin Papworth,Olivier Michielin,Ewan Brown,Pippa Corrie,Mark Harries,Satish Kumar,Agustin Martin-Clavijo,Mark R. Middleton,Poulam M. Patel,Toby Talbot,Sanjiv S. Agarwala,Paul B. Chapman,Robert M. Conry,Gary Doolittle,Tara C. Gangadhar,Sigrun Hallmeyer,Omid Hamid,Leonel Hernandez-Aya,Douglas B. Johnson,Frederic Kass,Tatjana Kolevska,Scott Lunin,April K.S. Salama,Branimir I. Sikic,Bradley Somer,David R. Spigel,Eric D. Whitman +128 more
TL;DR: The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAFV600 mutation-positive melanoma and the result was not significant because of the prespecified hierarchical prerequisite for the primary disease-free survival analysis of cohort 2 to show a significant health benefit.
190
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial
Jean-Yves Blay,Zsuzsanna Papai,Anthony W. Tolcher,Antoine Italiano,Didier Cupissol,Antonio Lopez-Pousa,Sant P. Chawla,Emmanuelle Bompas,Nada Babovic,Nicolas Penel,Nicolas Isambert,Arthur P. Staddon,Esma Saâda-Bouzid,Armando Santoro,Fabio Franke,Patrick Cohen,Solenn Le-Guennec,George D. Demetri +17 more
TL;DR: The combination of ombrabulin and cisplatin significantly improved progression-free survival; however, it did not show a sufficient clinical benefit in patients with advanced soft-tissue sarcomas to support its use as a therapeutic option.